Search Results
Found 1 results
510(k) Data Aggregation
(201 days)
BREAS PV 10I CPAP SYSTEM, MODEL PV 10I
The Breas PV10i CPAP System is intended to deliver Continuous Positive Airway Pressure (CPAP) therapy for the treatment of adult Obstructive Sleep Apnea (OSA).
In the treatment of sleep disorders, CPAP is well established and common practice as a means to prevent upper airways from collapsing and therefore avoid breathing problems associated with airway collapse and obstruction. There are a number of devices legally marketed in the United States for this application, including self-adjusting CPAP systems such as the predicate ResMed Sullivan Autoset T. The self-adjusting systems accommodate pressure requirements that may vary (e.g., as patients change bodies positions or enter different sleep stages).
The Breas PV10i CPAP is similar to the predicate Breas PV100 CPAP System, but with the addition of self-adjusting pressure features. Both Breas devices are microprocessor controlled based on firmware (embedded software). Both designs incorporate pressure sensors that monitor output pressure and provide feedback to the microprocessors. The PV10i also incorporates an airflow sensor and flow signal processing means in firmware to provide self-adjusting capability.
The therapy delivered by the Breas PV10i CPAP System can be either:
-
- Self-adjusting in response to variations in patient breathing patterns (CPAP "i" mode), or
-
- Set to a constant pressure level (constant CPAP mode).
The primary hardware component is a blower that generates airflow. The blower assembly consists of a brushless DC motor that drives a fan, entraining ambient air through a filter and pressurizing it to provide the prescribed airflow with CPAP for the patient. The microprocessor controls the motor and hence the speed of the fan.
The PV10i pressure range is 4 - 20 cmH20. Starting pressure and self-adjusting pressure limits are settable by clinical personnel in accordance with the patient's prescription.
The CPAP airflow is delivered via a single lumen outlet tube that may be connected to various non-invasive patient interfaces, such as nasal masks. To minimize CO2 rebreathing, masks or other interfaces permitting a leak flow of at least 12 liters/minute at the minimum output pressure setting of 4 cm of H20 are recommended for use with the PV10i.
The pressure transducer incorporated in the PV10i continuously monitors output pressure to the patient and reference ambient pressure. This enables the device to automatically compensate for altitude changes.
The PV10i has an auto-switching power supply that facilitates use in conjunction with international travel (100 - 240 VAC). It can also be used with an external 12 - 24 VDC power source when AC mains line voltage is not available. This DC power source capability is not intended as a battery power back-up system for any critical treatment applications. An accessory Remote Control Module may be connected that enables clinicians to operate the PV10i without using the control and setting panels on the device itself. A PC-based software program may also be supplied that provides an optional means for clinicians to set patient parameters (e.g., start and limit pressures) and track patient compliance.
The PV10i and its accessories are not sterile. The outer dimensions of the PV10i housing are 6.3 × 4.5 × 9.3 inches, and the device weighs 3.7 pounds.
The Breas PV10i CPAP System is intended to deliver Continuous Positive Airway Pressure (CPAP) therapy for the treatment of adult Obstructive Sleep Apnea (OSA). The studies performed aimed to demonstrate the device's efficacy and safety, particularly for its self-adjusting pressure features, and its substantial equivalence to predicate devices.
1. Table of Acceptance Criteria and Reported Device Performance:
The document describes several types of testing rather than explicit, quantified acceptance criteria in a pass/fail table for each feature. However, the overarching acceptance criterion is that the device meets its stated performance specifications and demonstrates substantial equivalence to predicate devices. The reported performance indicates this criterion was met.
Acceptance Criterion (Implied) | Reported Device Performance |
---|---|
Non-Clinical Testing | The device passed all non-clinical tests to verify stated performance specifications and addressed all Risk Analysis issues. |
Compliance with FDA Guidance | The device passed all tests for compliance with "Reviewer Guidance for Premarket Notification Submissions" (Nov 1993 draft), including Electrical Safety (IEC 601), Electromagnetic Compatibility (EMC), Mechanical Safety, Environmental, and Functional testing. |
Software Validation | All device software (embedded and optional PC software) passed all tests in accordance with FDA's "Guidance for the content of Premarket Submissions for Software Contained in Medical Devices" (May 29, 1998). |
Clinical Efficacy (AHI Reduction) | Three-way crossover study: No significant differences in sleep or ventilatory variables between PV10i, predicate ResMed AutoSet®T, and constant CPAP. Mean AHI for PV10i was 6.8 (compared to 4.0 for Autoset T and 1.8 for constant CPAP). Randomized treatment study: PV10i patient group showed mean AHI reduction from 55.6 initially to 6.3 after titration and 7.5 after 6 months. Comparable values for predicate AutoSet T were 56.5 -> 5.5 -> 3.6, and for predicate Goodnight 418P were 48.5 -> 4.3 -> 3.4. All self-adjusting CPAP devices were judged efficient. |
Clinical Efficacy (Pressure Applied) | Three-way crossover study: PV10i applied lower mean pressure (6.7) compared to AutoSet®T (8.4) (p |
Ask a specific question about this device
Page 1 of 1